40
Participants
Start Date
April 17, 2024
Primary Completion Date
February 15, 2028
Study Completion Date
March 28, 2031
Mavacamten
Specified dose on specified days
Placebo
Specified dose on specified days
Local Institution - 0020, Sydney
Local Institution - 0042, Clayton
Local Institution - 0014, Barcelona
Local Institution - 0010, New Hyde Park
Local Institution - 0018, Berlin
Local Institution - 0051, Genova
Local Institution - 0039, Durham
Local Institution - 0025, Madrid
Local Institution - 0015, Charlotte
Local Institution - 0026, Pessac
Local Institution - 0034, Memphis
Local Institution - 0029, Columbus
Local Institution - 0019, Cincinnati
Local Institution - 0002, Ann Arbor
Local Institution - 0016, Florence
Local Institution - 0037, St Louis
Local Institution - 0022, Paris
Local Institution - 0054, Houston
Local Institution - 0045, Austin
Local Institution - 0027, Napoli
Local Institution - 0006, Munich
Local Institution - 0017, Birmingham
Local Institution - 0050, Phoenix
Local Institution - 0032, Los Angeles
Local Institution - 0008, Los Angeles
Local Institution - 0033, Palo Alto
Local Institution - 0044, San Diego
Local Institution - 0038, Aurora
Local Institution - 0031, St. Petersburg
Local Institution - 0053, Atlanta
Local Institution - 0013, Chicago
Local Institution - 0009, Indianapolis
Local Institution - 0043, Boston
Local Institution - 0052, Morristown
Local Institution - 0024, New York
Local Institution - 0036, New York
Local Institution - 0040, The Bronx
Local Institution - 0001, Cleveland
Local Institution - 0030, Philadelphia
Local Institution - 0005, Pittsburgh
Local Institution - 0003, Salt Lake City
Local Institution - 0012, Charlottesville
Local Institution - 0041, Edmonton
Local Institution - 0046, Toronto
Local Institution - 0047, Dublin 12, D12 N512
Local Institution - 0049, Belfast
Local Institution - 0007, London
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY